Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
September 05, 2023 08:30 ET
|
Travere Therapeutics, Inc.
• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments• Mirum has acquired Travere’s rights and assets related to Cholbam® and...
Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress
May 17, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal...
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
May 16, 2022 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New...
Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer
January 04, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig...
Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress
October 28, 2021 16:01 ET
|
Travere Therapeutics, Inc.
Recently reported positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgA nephropathy Following pre-NDA interactions with FDA, NDA submission of...
Travere Therapeutics to Report Third Quarter 2021 Financial Results
October 14, 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the...
Travere Therapeutics Announces Transition of Chief Medical Officer
October 12, 2021 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief medical officer, Noah Rosenberg, M.D., has chosen to transition for personal...
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
September 14, 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective...
Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
August 16, 2021 07:00 ET
|
Travere Therapeutics, Inc.
Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy...
Travere Therapeutics Reports Second Quarter 2021 Financial Results
July 29, 2021 16:01 ET
|
Travere Therapeutics, Inc.
Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track...